The study, coordinated by Professor Pozzilli and Dr Rocky Strollo ofUniversità Campus Bio-Medico di Roma, has shown that the majority of subjects with type 1 diabetes present antibodies against a particular form of 'modified' insulin even up to eleven years before the onset of the disease. The predictive power of a new biomarker has been revealed, found in 91 percent of initially healthy subjects who developed diabetes over time. First test already under development: it will be carried out with a blood sample.
Here you can download the photos of the researchers UCBM
Rome, 18 May 2017 - Could be soon available a test able to find out, through a simple blood sample, if there is a concrete risk of falling ill 1 type diabetes. An opportunity made possible thanks to discovery of a particular antibody capable of predicting the onset of this form of diabetes, the so-called 'children's diabetes', already in healthy subjects.
A study conducted by Italian researchers in collaboration with the Queen Mary University of London, just published in the scientific journal Diabetology, the official body of the European Association for the Study of Diabetes (EASD), has certified the efficacy of this biomarker in 91 percent of cases. So it could be thereat first 'spy' really useful on a clinical level to predict the possible onset of this serious disease in the general population. A pathology which only in Italy, it affects over 300 people, with an annual growth of 3 percent in the number of young people diagnosed (source: Ministry of Health).
Starting point: data from the 'ABIS' study
Scientific work, conducted under the guidance of Professor Paolo Pozzilli, Professor of Endocrinology and Metabolic Diseases at l'Università Campus Bio-Medico di Roma, has benefited from data collected by the 'ABIS' study (All Babies in Southeast Sweden) from Linköping University, which he followed for about 20 years a population of over 17 thousand subjects, evaluating over time, on this maxi-sample, the incidence in the development of type 1 diabetes. To achieve this, the individuals were monitored with blood draws performed periodically, since birth.
The research conducted by Professor Pozzilli's group used the serum samples of these subjects, checking for the presence of this auto-antibody in the blood – aimed against a form of insulin modified by oxidative processes – together with that of the other four types of 'standard' biomarkers, currently used for the diagnosis of type 1 diabetes. “In the recent past – explains Pozzilli – we already had experimentally demonstrated on diabetic patients at diagnosis that the presence of auto-antibodies directed to the so-called oxidized insulin, or 'rusty' from oxygen radicals generated during an inflammatory process, had a higher diagnostic power than to those directed against the natural, unmodified form of insulin, resulting in results positive in about 84 percent of patients, compared to 61 percent obtained with antibodies to normal insulin”.
91 percent of subjects who develop the disease are autoantibody positive
Researchers have directed their scientific attention towards this particular modified insulin, no longer recognized by the body as a native product and therefore 'bombarded' by the immune system, placing it as a new target of the autoimmune response in the so-called childhood diabetes. Starting from this data, the group coordinated by Professor Pozzilli has evaluated the efficacy of the new biomarker on healthy subjects, followed from the neonatal age. "The ability – clarifies Pozzilli – to indicate a future case of type 1 diabetes based on the presence in the blood of this auto-antibody, called oxPTM-INS-Ab, was very high, identifying almost all cases. The results therefore suggest that this new auto-antibody could become an important ally in being able to predict which people are most at risk of contracting this form of diabetes, sporadic and so far unpredictable in time to avoid serious damage to pancreatic beta-cells”.
I experimental data have shown that to develop antibodies to 'oxidized' insulin 21 out of 23 children actually developed type 1 diabetes. "This study – adds the Dr. Rocky Strollo, endocrinologist and researcher at UCBM, as well as first signature of the work It provides new insights into the mechanisms underlying this form of diabetes, because it demonstrates that pancreatic autoimmunity can be induced by oxidative changes of insulin and that this can happen many years before the clinical onset of the pathology, even up to eleven. The test we developed for the dosage of oxidized insulin antibodies is highly sensitive and specific for the diagnosis and early identification of type 1 diabetes".
“Thank you for this discovery – continues Pozzilli – we will soon be able to provide support to subjects who feel the need to know what their level of susceptibility to developing the disease is: I think, above all, a how many have sick brothers or sisters. For the latter, in fact, the'incidence, which in the general population is 2-3 per thousand, can increase up to 10 times".
What is childhood diabetes?
Type 1 diabetes is one autoimmune pathology which brings the immune system to recognize the cells of the pancreas that produce insulin as foreign and harmful (beta-cells) and, therefore, ad attack and destroy them, up to cause an absolute deficit of this hormone in the body.
The disease, sometimes favored by genetic predispositions or exposure to as yet unidentified environmental factors, such as probably viral infections, generally develops during the adolescent years, but can also appear in neonatal age or in young adults: about 30 percent of type 1 diabetes cases are diagnosed in adulthood. There is currently no definitive cure, other than surrogate insulin in subjects who have now lost functioning beta-cells in the pancreas.
Blood draw test
I researchers are now working to make the predictive test available as soon as possible. The peculiarity of the system, in fact, lies in the specific immunoenzymatic dosage identified, which falls within those of the ELISA type (Enzyme-Linked Immuno-Sorbent Assay), an immunological analysis method more practical, safe and economical than the radioimmunoassay necessary for the other biomarkers used up to now for the diagnosis of type 1 diabetes.
Since this discovery, scientists hope to be able to dedicate new perspectives to the preparation of clinical trials in which individuals who test positive for the antibody are involved, to verify any conditions capable of delaying the onset of the disease. "As well as - concludes Pozzilli - to search for new solutions that can prevent the death of all their pancreatic beta-cells". Thus avoiding the obligation of external intake of insulin to a growing number of 'baby-patients'. An inconvenience that forces those who need it to resort to injections of this hormone for life.
R Strollo, C Vinci, N Napoli, P Pozzilli, J Ludvigsson, A Nissim.
Antibodies to post-translationally modified insulin as a novel biomarker for prediction of type 1 diabetes in children.
Diabetology 2017. DOI: 10.1007/s00125-017-4296-1